[go: up one dir, main page]

ATE409047T1 - Humanisierte antikörper - Google Patents

Humanisierte antikörper

Info

Publication number
ATE409047T1
ATE409047T1 AT02726750T AT02726750T ATE409047T1 AT E409047 T1 ATE409047 T1 AT E409047T1 AT 02726750 T AT02726750 T AT 02726750T AT 02726750 T AT02726750 T AT 02726750T AT E409047 T1 ATE409047 T1 AT E409047T1
Authority
AT
Austria
Prior art keywords
humanized
humanized antibodies
disclosed
making
antibody
Prior art date
Application number
AT02726750T
Other languages
English (en)
Inventor
Paul Robert Hinton
Maximilano Vasquez
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE409047T1 publication Critical patent/ATE409047T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02726750T 2001-04-30 2002-04-26 Humanisierte antikörper ATE409047T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28765301P 2001-04-30 2001-04-30

Publications (1)

Publication Number Publication Date
ATE409047T1 true ATE409047T1 (de) 2008-10-15

Family

ID=23103802

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02726750T ATE409047T1 (de) 2001-04-30 2002-04-26 Humanisierte antikörper

Country Status (7)

Country Link
US (1) US7320790B2 (de)
EP (1) EP1385544B1 (de)
AT (1) ATE409047T1 (de)
AU (1) AU2002257162A1 (de)
DE (1) DE60229051D1 (de)
ES (1) ES2312569T3 (de)
WO (1) WO2002088307A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
MY139983A (en) * 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
DE602004027348D1 (de) * 2003-02-10 2010-07-08 Applied Molecular Evolution Abeta-bindende moleküle
CA2520853A1 (en) * 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
TWI374893B (en) 2003-05-30 2012-10-21 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
TWI364458B (en) 2004-08-27 2012-05-21 Wyeth Res Ireland Ltd Production of tnfr-lg
US7294484B2 (en) 2004-08-27 2007-11-13 Wyeth Research Ireland Limited Production of polypeptides
KR20070073885A (ko) * 2004-10-05 2007-07-10 뉴랄랩 리미티드 재조합 단백질 생산을 향상시키는 방법 및 조성물
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
CA2589860A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
EP2388274A1 (de) 2005-06-17 2011-11-23 Janssen Alzheimer Immunotherapy Verfahren zur Reinigung von Anti-A-Beta-Antikörpern
CA2848662A1 (en) 2005-06-30 2007-01-11 Abbvie Inc. Il-12/p40 binding proteins
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
AU2013200177B2 (en) * 2005-11-30 2014-10-02 Abbvie Deutschland Gmbh & Co Kg Monoclonal antibodies against amyloid beta protein and uses thereof
WO2007068412A2 (en) 2005-12-12 2007-06-21 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
ES2368591T3 (es) 2005-12-12 2011-11-18 F. Hoffmann-La Roche Ag Anticuerpos contra beta amiloide con glicosilación en la región variable.
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7892544B2 (en) 2006-07-14 2011-02-22 Ac Immune Sa Humanized anti-beta-amyloid antibody
US7744890B2 (en) 2006-10-12 2010-06-29 Wyeth Llc Methods and compositions with reduced opalescence
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
AU2008267038B2 (en) * 2007-06-12 2014-08-07 Ac Immune S.A. Humanized antibodies to amyloid beta
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
SI2182983T1 (sl) 2007-07-27 2014-09-30 Janssen Alzheimer Immunotherapy Zdravljenje amiloidogenih bolezni s humaniziranimi protitelesi proti abeta
WO2009048539A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
AU2008343855B2 (en) 2007-12-21 2013-08-15 Amgen Inc. Anti-amyloid antibodies and uses thereof
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
BR112012008346B1 (pt) 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
ES2481823T3 (es) 2010-03-10 2014-07-31 Probiodrug Ag Inhibidores heterocíclicos de glutaminil ciclasa (QC, EC 2.3.2.5)
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
EP2938725B1 (de) * 2012-12-31 2017-08-23 Boehringer Ingelheim International GmbH Heterologes intron in einer immunoglobulindomäne
WO2014102101A1 (en) * 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
EP2938726B1 (de) 2012-12-31 2017-09-27 Boehringer Ingelheim International GmbH Heterologes intron mit einem signalpeptid
EP2938728B1 (de) * 2012-12-31 2020-12-09 Boehringer Ingelheim International GmbH Künstliche introne
KR102162323B1 (ko) 2013-09-09 2020-10-06 캐님가이드 테라퓨틱스 에이비 면역계 조절제
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
WO2016144650A1 (en) 2015-03-06 2016-09-15 Canimguide Therapeutics Ab Immune system modulators and compositions
ES2908009T3 (es) 2015-06-24 2022-04-27 Hoffmann La Roche Anticuerpos anti-receptor de transferrina con afinidad adaptada
CN114014936A (zh) 2015-10-02 2022-02-08 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
EP3461819B1 (de) 2017-09-29 2020-05-27 Probiodrug AG Hemmer der glutaminylcyclase
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
WO2025032070A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Anti-a-beta protein antibodies, methods and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5538845A (en) * 1992-02-05 1996-07-23 Athena Neurosciences, Inc. Beta-amyloid peptide production inhibitors and methods for their identification
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
US5589154A (en) * 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US5688651A (en) * 1994-12-16 1997-11-18 Ramot University Authority For Applied Research And Development Ltd. Prevention of protein aggregation
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
NZ337765A (en) 1997-04-09 2001-09-28 Mindset Biopharmaceuticals Usa Recombinant antibodies having specificity for beta-amyloid N-terminus and C-terminus and use in treating Alzheimer's Disease
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
ES2311131T3 (es) * 1997-08-08 2009-02-01 The Regents Of The University Of California Tratamiento de la fibrosis hepatico con anticuerpos contra la integrina alfa-v-beta6.
US6175057B1 (en) * 1997-10-08 2001-01-16 The Regents Of The University Of California Transgenic mouse model of alzheimer's disease and cerebral amyloid angiopathy
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
KR100701580B1 (ko) 1998-05-21 2007-03-30 유니버시티 오브 테네시 리서치 파운데이션 항-아밀로이드 항체를 이용한 아밀로이드 제거 방법들
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
PT1409654E (pt) 1999-06-16 2008-11-25 Boston Biomedical Res Inst Controlo imunológico dos níveis de beta-amilóide in vivo
AU784568B2 (en) 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
SK288711B6 (sk) * 2000-02-24 2019-11-05 Univ Washington Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2002088306A2 (en) * 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies

Also Published As

Publication number Publication date
US7320790B2 (en) 2008-01-22
US20050142131A1 (en) 2005-06-30
EP1385544A2 (de) 2004-02-04
EP1385544A4 (de) 2005-11-02
ES2312569T3 (es) 2009-03-01
DE60229051D1 (de) 2008-11-06
WO2002088307A3 (en) 2003-07-24
WO2002088307A2 (en) 2002-11-07
EP1385544B1 (de) 2008-09-24
AU2002257162A1 (en) 2002-11-11

Similar Documents

Publication Publication Date Title
ATE409047T1 (de) Humanisierte antikörper
EP1385545A4 (de) Humanisierte antikörper
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
CY1111542T1 (el) Αντισωματα εξουδετερωσης του rsv υπερυψηλης συγγενειας
ATE492563T1 (de) Vollständige humane monoklonale antikörper gegen il-13
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
AT500379B8 (de) Tau-proteine
WO2007067730A3 (en) Human monoclonal antibodies to protein tyrosine kinase 7 ( ptk7 ) and their use
DE60237778D1 (de) Antikörper gegen kdr, deren herstellung und verwendungen
DE60220719D1 (de) Antikörper gegen das muc18-antigen
DE60335022D1 (de) Internalisierende Antikörper spezifisch für das RAAG10 Zelloberflächenziel
NO20053860D0 (no) COP 1 for behandling av inflammatorisk tarmsykdom.
WO2006014638A3 (en) ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
ATE517920T1 (de) Humanisierte antikörper gegen interferon-alpha- rezeptor-1 (ifnar-1)
ATE382683T1 (de) Monoklonales antikörper gegen das hcv kernantigen
ATE291086T1 (de) An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
DK1895017T3 (da) Anvendelse af A33-antigener og JAM-IT
EP1411962A4 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
EA200300246A1 (ru) Ген и белок, ассоциированные с шизофренией
NO20023670D0 (no) Antistoff med spesifisitet for colonkreft
FR2856595B1 (fr) Methodes et compositions pour le traitement de deficits cognitifs.
NZ629387A (en) Monoclonal antibodies against amyloid beta protein and uses thereof
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
WO2002102990A3 (en) Fibroblast growth factor and nucleic acid encoding same

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties